Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-11-20T07:21:18.233Z Has data issue: false hasContentIssue false

Cyproheptadine in treatment of autism

Published online by Cambridge University Press:  16 April 2020

S.-S. Gudarzi*
Affiliation:
Department of Psychiatry, Shaheed Beheshti University of Medical Sciences, Tehran, 16179, Iran
M. Yasamy
Affiliation:
Department of Psychiatry, Shaheed Beheshti University of Medical Sciences, Tehran, 16179, Iran
S. Akhondzadeh
Affiliation:
Department of Psychiatry, Tehran University of Medical Sciences, Tehran, Iran
*
*Corresponding author. Department of Psychiatry, Imam Hossein Hospital, Sh. Madani St., Tehran, 16179, Iran. E-mail address: [email protected] (S.S. Gudarzi).
Get access

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Case Reports
Copyright
Copyright © Éditions scientifiques et médicales Elsevier SAS 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Akhondzadeh, SMohammadi, MAAmini-Nooshabadi, HDavari-Ashtiani, . Cyproheptadine in treatment of chronic schizophrenia: a double-blind, placebo-controlled study. J Clin Pharm Ther 1999;24:49–52.CrossRefGoogle ScholarPubMed
Akhondzadeh, SThe 5-HT hypothesis of schizophrenia. Idrugs 2001;4:295–300.Google ScholarPubMed
Goudie, AJSnith, JADiscriminative stimulus properties of antipsychotics. Pharmacol Biochem Behav 1999;64:193–201.CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.